Supernus Invests $400 Million to Acquire New Parkinson’s Assets from Adamas
On October 11th, Maryland-based Supernus Pharmaceuticals announced that it is acquiring Adamas Pharmaceuticals in an all-cash deal amounting to approximately $400 million. This roughly comes out to $9.10 per share, which includes an upfront payment of $8.10 per share.
An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.
An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.
GO Prime with only $1.49 now
LATEST
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115